Global anti-diabetic revenue by top ten pharmaceutical companies 2017 and 2024

The top pharmaceutical companies based on global anti-diabetic revenue include big-name pharmaceutical leaders such as Novo Nordisk and Eli Lilly. As of 2017, Novo Nordisk was the top global anti-diabetic revenue generator with over 13.7 billion U.S. dollars in revenue for that year. Novo Nordisk is projected to continue being the top anti-diabetic pharmaceutical company by 2024. They are projected to make about 21 billion U.S. dollars in anti-diabetic pharmaceuticals revenue in the year 2024.

Diabetes treatments and prevalence

Diabetes is a chronic illness caused by the pancreas not producing enough insulin or the body not effectively using insulin. The global prevalence of diabetes in 2017 was about 8.8 percent and that is expected to increase significantly by 2045. Though not all countries are affected equally. Many Pacific Island nations have a significantly higher prevalence of diabetes than the rest of the world. Likewise, not all countries have the same standards of care or costs for care. Norway, Switzerland and the U.S. have the some of the highest costs per person with diabetes as of 2017.

Top diabetes pharmaceuticals

There are many types of treatments for diabetes. As of 2017, Novo Nordisk’s NovoRapid insulin held the highest share among all anti-diabetic products on the market. NovoRapid is primarily used in the treatment of type I diabetes. Other types of insulin are also among the top anti-diabetic products. When based on revenue generated, the top anti-diabetic products included Eli Lilly’s Trulicity and Boehringer Ingelheim’s Jardiance, medications used primarily in the treatment of type 2 diabetes.

Top 10 pharmaceutical companies by global anti-diabetic revenue in 2017 and 2024

20172024*
---
---
---
---
---
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

June 2018

Region

Worldwide

Survey time period

as of May 2018

Supplementary notes

* Projected.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Eli Lilly"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.